|
gptkbp:instanceOf
|
gptkb:drug
histamine H2-receptor antagonist
|
|
gptkbp:approvalYear
|
1983
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:A02BA02
|
|
gptkbp:brand
|
gptkb:Zantac
|
|
gptkbp:CASNumber
|
gptkb:66357-35-5
|
|
gptkbp:chemicalClass
|
gptkb:furan
nitro compound
|
|
gptkbp:contraindication
|
hypersensitivity to ranitidine
|
|
gptkbp:developedBy
|
1977
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Holdings
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:sugar
gptkb:tablet
injection
|
|
gptkbp:hasMolecularFormula
|
C13H22N4O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ranitidine
|
|
gptkbp:KEGGID
|
gptkb:D00427
|
|
gptkbp:legalStatus
|
withdrawn in many countries
|
|
gptkbp:marketedAs
|
1981
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
blocks H2 receptors in stomach
|
|
gptkbp:MedlinePlusID
|
a601106
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 1 month
|
|
gptkbp:overdoseSymptoms
|
vomiting
restlessness
tachycardia
|
|
gptkbp:patentExpired
|
1997
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00863
CHEMBL685
3001055
|
|
gptkbp:recall
|
gptkb:FDA
April 2020
|
|
gptkbp:reduces
|
gastric acid secretion
|
|
gptkbp:replacedBy
|
gptkb:famotidine
|
|
gptkbp:retired
|
NDMA contamination
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
constipation
dizziness
fatigue
headache
|
|
gptkbp:UNII
|
884KT10YB7
|
|
gptkbp:usedFor
|
treating gastroesophageal reflux disease
treating Zollinger-Ellison syndrome
treating peptic ulcer disease
|
|
gptkbp:withdrawn
|
2019
|
|
gptkbp:bfsParent
|
gptkb:famotidine
gptkb:Tagamet
gptkb:H2_blocker
|
|
gptkbp:bfsLayer
|
6
|